 |
A new once-weekly duo for HIV treatment shows promising results
TPAN | December 23, 2025
|
|
GSK enters agreement with U.S. government to lower drug prices and expand access to ...
ViiV Healthcare | December 19, 2025
|
|
[Press release] MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection
European AIDS Treatment Group | December 19, 2025
|
|
Subcutaneous Lenacapavir in People with Multidrug-Resistant HIV-1: 156 Week Results of ...
Oxford Academic | December 19, 2025
|
|
FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance
CNN | December 12, 2025
|
|
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
EATG | December 6, 2025
|
|
Common water pill may help HIV medicines work faster and reduce inflammation
EATG | December 3, 2025
|
|
Long-term HIV control: Could this combination therapy be the key?
EATG | December 3, 2025
|
|
Merck's oral HIV treatment as effective as Gilead's Biktarv
The Jerusalem Post | November 24, 2025
|
|
Systemic inflammation in suppressed HIV similar after switch to 3-drug ART
EATG | November 22, 2025
|
|
Systemic Inflammation in Suppressed HIV Similar After Switch to 3-Drug ART
IDA | November 21, 2025
|
|
Merck's oral HIV treatment meets main goal in late-stage study
Reuters | November 19, 2025
|
|
Antibody drugs show promise for treating bird flu and HIV
Nature | November 5, 2025
|
|
CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies
HIV+HEP | October 22, 2025
|
|
HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price
IDSA | October 19, 2025
|
|
Gilead to present data on potential first weekly oral treatment for HIV
Yahoo! News | October 15, 2025
|
|
Once-Weekly Oral ISL/LEN Combo for HIV Treatment Found Safe and Effective, With High Adherence
Infectious Disease Special Edition | October 17, 2025
|
|
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with...
ViiV Healthcare | October 17, 2025
|
|
Novel HIV Combo Therapy of Lenacapavir and 2 bNAbs Found Effective, Well Tolerated in in Phase 2 Trial
Infectious Disease Special Edition | October 17, 2025
|
|
Integrase inhibitors maintain efficacy despite “outside” mutations, UK study finds
European AIDS Treatment Group | October 12, 2025
|
|
'We can end HIV': Groundbreaking preventative drug to be rolled out for $40 a year from 2027
France24 | September 25, 2025
|
|
Gates Foundation partners with Indian manufacturer to drive down cost of, accelerate access to groundbreaking HIV prevention tool
Gates Foundation | September 24, 2025
|
|
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
UNAIDS | September 24, 2025
|
|
HIV Drug Resistance Is Declining Over Time
POZ Magazine | September 24, 2025
|
|
From Bench to Breakthrough: How Curiosity Led to an Extraordinarily Effective HIV Drug
University of Utah Health | September 22, 2025
|
|
New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis
News Medical | August 26, 2025
|
|
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Gilead | August 26, 2025
|
|
HIV: Monthly PrEP Drug Candidate Shows Promise
Newsweek | August 26, 2025
|
|
HIV Treatment Overview
NIH | August 20, 2025
|
|
Lenacapavir will not end the HIV epidemic in the current US political climate
The Lancet | August 2025
|
|
Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science...
NIH | August 5, 2025
|
|
IAS 2025: Pharmacists Steer Modern HIV Care Through Co-Infection Management
Pharmacy Times | July 29, 2025
|
|
WHO urges rollout of first long-acting HIV prevention jab
UN | July 14, 2025
|
|
Viiv Healthcare Presents New Data Demonstrating Positive Real-World Impact of Its Innovative Long-Acting Injectables for HIV at IAS 2025
ViiV | July 8, 2025
|
|
The Drug That Could Revolutionize the Fight Against H.I.V.
The New Yorker | June 24, 2025
|
| |
|
|
|
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Gilead | June 18, 2025
|
|
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
Contagion Live | June 18, 2025
|
|
‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers
The Guardian | June 17, 2025
|
|
FDA Alert: Infectious Diseases Drug News Roundup
ISA | June 13, 2025
|
|
Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the...
HIV.gov | June 12, 2025
|
|
Gilead hit with FDA clinical hold for batch of HIV trials
Yahoo | June 11, 2025
|
|
Affordable HIV drug shows promise in improving vision for diabetic eye disease
News-Medical | May 27, 2205
|
|
HIV drug can improve vision in patients with common diabetes complication
NIH | May 27, 2025
|
|
Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease
IDA | May 21, 2025
|
|
Certain HIV Meds Linked to Reduced Alzheimer’s Risk
Medscape | May 16, 2025
|
|
Expanding HIV Prevention: Overcoming Barriers and Embracing Long-Acting PrEP
Contagion Live | May 16, 2025
|
|
Alzheimer's disease could be prevented by antiviral drug already on market
Fox News | May 15, 2025
|
|
IL plan to remove prior authorization from some HIV drugs passes the House
News 25 Illinois | April 14, 2025
|
|
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire
Aidsmap | April 10, 2025
|
|
HIV testing requirements must be simplified for injectable PrEP to have a future
Aidsmap | March 21, 2025
|
|
Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks
US News & World Report | April 29, 2025
|
|
Unhealthy Alcohol Use and HIV Preexposure Prophylaxis—Opportunities for Integrated Care
JAMA | April 25, 2025
|
|
Real-World Evidence Supports DTG+3TC for ART in Diverse HIV Populations
IDA | April 25, 2025
|
|
Gilead posts profit, says HIV prevention drug on track for mid-June
Reuters | April 24, 2025
|
|
CMV antiviral may reduce inflammation and improve immune function in people with HIV
Aidsmap | March 21, 2025
|
|
First-in-Human Study of Long-Acting Injectable HIV Nanoparticle Combination Therapy
Contagion Live | March 19, 2025
|
|
Drug Regimen For HIV Shows Non-Inferiority to Antiretroviral Therapies
Drug Topics | March 14, 2025
|
|
Merck releases positive phase 3 data on daily oral HIV drug
MSN | March 13, 2025
|
|
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Managed Healthcare Executive | March 13, 2025
|
|
ViiV Healthcare announces new implementation study data showing zero cases of HIV with apretude, the only long-acting injectable approved for...
ViiV Healthcare | March 12, 2025 |
|
Gilead data suggests once-yearly shot of PrEP drug blocks HIV infection
STAT News | March 11, 2025
|
|
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Gilead | February 18, 2025
|
|
This is what happens to the body when HIV drugs are stopped for millions of people
AP | February 13, 2025
|
|
What's happening with the anti-HIV program PEPFAR? It depends whom you ask
NPR | February 13, 2025
|
|
US spells out life-saving HIV treatment that can continue during aid pause
Reuters | February 1, 2025
|
|
What to Do if You Can’t Get Your HIV Medication Costs Covered
The Body | January 29, 2025
|
|
Combination of Dolutegravir, Lamivudine Effective in People Living With HIV
American Journal of Managed Care | January 22, 2025
|
|
NIAID Study Describes Successful Treatment Regimen for Person with Multidrug-Resistant HIV
NIH | January 16, 2025
|
|
DoxyPEP Tied to Decreases in Sexually Transmitted Infections
Health Day | January 7, 2025
|
|
WHO to Develop Lenacapavir and HIV Testing Guidelines
Managed Healthcare | January 7, 2025
|
|
Twice-Yearly Lenacapavir Could Support HIV Prevention in Vulnerable Populations
JAMA | January 3, 2025
|
| |
|
|
